日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Plasminogen Activator Inhibitor-1 Mediates Tolerance to Anti-PD-1 Immunotherapy in Non-Small Cell Lung Cancer.

纤溶酶原激活物抑制剂-1介导非小细胞肺癌对PD-1抗免疫疗法的耐受性。

Sumii Masahiko, Masuda Takeshi, Shimoji Kiyofumi, Yamaguchi Kakuhiro, Sakamoto Shinjiro, Horimasu Yasushi, Mimae Takahiro, Nakashima Taku, Iwamoto Hiroshi, Miyata Yoshihiro, Hamada Hironobu, Okada Morihito, Miyata Toshio, Hattori Noboru

Effectiveness and safety of combination immunotherapy with or without ipilimumab according to PD-L1 expression in patients with non-small cell lung cancer: a multi-center retrospective cohort study

根据PD-L1表达情况评估联合免疫疗法(含或不含伊匹木单抗)治疗非小细胞肺癌患者的有效性和安全性:一项多中心回顾性队列研究

Nomura, Akio; Masuda, Takeshi; Shimoji, Kiyofumi; Takao, Shun; Izumi, Yusuke; Araki, Yusuke; Takayama, Yusuke; Masuda, Ken; Yamaguchi, Kakuhiro; Sakamoto, Shinjiro; Horimasu, Yasushi; Nakashima, Taku; Iwamoto, Hiroshi; Senoo, Tadashi; Shoda, Hiroyasu; Ishikawa, Nobuhisa; Yamasaki, Masahiro; Hamada, Hironobu; Okada, Morihito; Hattori, Noboru

Tumor-Bearing Status Accelerates Bleomycin-Induced Pulmonary Inflammation via Endothelial Activation.

肿瘤状态通过内皮细胞活化加速博来霉素诱导的肺部炎症。

Isoyama Shoko, Yamaguchi Kakuhiro, Iwamoto Hiroshi, Horimasu Yasushi, Funaishi Kunihiko, Shimoji Kiyofumi, Sakamoto Shinjiro, Masuda Takeshi, Nakashima Taku, Ohshimo Shinichiro, Hamada Hironobu, Hattori Noboru

Systemic miR-26a deficiency attenuates pulmonary fibrosis via PTEN upregulation and downstream TIMP-1 suppression

系统性 miR-26a 缺乏通过上调 PTEN 和抑制下游 TIMP-1 来减轻肺纤维化

Hamada, Arisa; Shimoji, Kiyofumi; Nakashima, Taku; Yamaguchi, Kakuhiro; Sakamoto, Shinjiro; Horimasu, Yasushi; Masuda, Takeshi; Iwamoto, Hiroshi; Hamada, Hironobu; Guo, Yun; Yasuda, Tomoharu; Miyaki, Shigeru; Hattori, Noboru

Predictive Value of Circulatory Total VEGF-A and VEGF-A Isoforms for the Efficacy of Anti-PD-1/PD-L1 Antibodies in Patients with Non-Small-Cell Lung Cancer

循环总 VEGF-A 和 VEGF-A 亚型对非小细胞肺癌患者抗 PD-1/PD-L1 抗体疗效的预测价值

Hirakawa, Tetsu; Yamaguchi, Kakuhiro; Funaishi, Kunihiko; Shimoji, Kiyofumi; Sakamoto, Shinjiro; Horimasu, Yasushi; Masuda, Takeshi; Nakashima, Taku; Iwamoto, Hiroshi; Hamada, Hironobu; Yamada, Shingo; Hattori, Noboru

Clinical impact of hypomagnesemia induced by necitumumab plus cisplatin and gemcitabine treatment in patients with advanced lung squamous cell carcinoma: a subanalysis of the NINJA study

奈西妥单抗联合顺铂和吉西他滨治疗晚期肺鳞状细胞癌患者引起的低镁血症的临床影响:NINJA研究的亚组分析

Tanzawa, Shigeru; Yoshioka, Hiroshige; Misumi, Toshihiro; Miyauchi, Eisaku; Ninomiya, Kiichiro; Murata, Yasunori; Takeshita, Masafumi; Kinoshita, Fumihiko; Fujishita, Takatoshi; Sugawara, Shunichi; Kawashima, Yosuke; Hashimoto, Kazuki; Mori, Masahide; Miyanaga, Akihiko; Hayashi, Anna; Tanaka, Hisashi; Honda, Ryoichi; Nojiri, Masafumi; Sato, Yuki; Hata, Akito; Ishikawa, Nobuhisa; Kozuki, Toshiyuki; Kawamura, Takahisa; Saito, Go; Yamaguchi, Teppei; Asada, Kazuhiro; Tetsumoto, Satoshi; Tanaka, Hiroshi; Watanabe, Satoshi; Umeda, Yukihiro; Yamaguchi, Kakuhiro; Nishii, Kazuya; Tsuruno, Kosuke; Misumi, Yuki; Kuraishi, Hiroshi; Yoshihara, Ken; Nakao, Akira; Kubo, Akihito; Yokoyama, Toshihiko; Watanabe, Kana; Seki, Nobuhiko

Skin disorder within 30 days is a favorable prognostic factor in patients with lung squamous cell carcinoma treated with necitumumab plus gemcitabine and cisplatin: a sub-analysis of the NINJA study

30天内出现皮肤疾病是接受奈西妥单抗联合吉西他滨和顺铂治疗的肺鳞状细胞癌患者的良好预后因素:NINJA研究的亚组分析

Kinoshita, Fumihiko; Tanzawa, Shigeru; Misumi, Toshihiro; Yoshioka, Hiroshige; Miyauchi, Eisaku; Ninomiya, Kiichiro; Murata, Yasunori; Takeshita, Masafumi; Yamaguchi, Masafumi; Sugawara, Shunichi; Kawashima, Yosuke; Hashimoto, Kazuki; Mori, Masahide; Miyanaga, Akihiko; Hayashi, Anna; Tanaka, Hisashi; Honda, Ryoichi; Nojiri, Masafumi; Sato, Yuki; Yamamoto, Ken; Masuda, Ken; Kozuki, Toshiyuki; Kawamura, Takahisa; Suzuki, Takuji; Yamaguchi, Teppei; Asada, Kazuhiro; Tetsumoto, Satoshi; Tanaka, Hiroshi; Watanabe, Satoshi; Umeda, Yukihiro; Yamaguchi, Kakuhiro; Kuyama, Shoichi; Tsuruno, Kosuke; Misumi, Yuki; Kuraishi, Hiroshi; Yoshihara, Ken; Nakao, Akira; Kubo, Akihito; Yokoyama, Toshihiko; Watanabe, Kana; Seki, Nobuhiko

Serum Soluble Toll-Like Receptor 4 is a Predictive Biomarker for Acute Exacerbation and Prognosis of Idiopathic Pulmonary Fibrosis: A Retrospective Study

血清可溶性 Toll 样受体 4 是特发性肺纤维化急性加重和预后的预测性生物标志物:一项回顾性研究

Kitadai, Erika; Yamaguchi, Kakuhiro; Iwamoto, Hiroshi; Shimoji, Kiyofumi; Sakamoto, Shinjiro; Horimasu, Yasushi; Masuda, Takeshi; Nakashima, Taku; Ohshimo, Shinichiro; Hamada, Hironobu; Hattori, Noboru

HMGB1 assists the predictive value of tumor PD-L1 expression for the efficacy of anti-PD-1/PD-L1 antibody in NSCLC

HMGB1有助于提高肿瘤PD-L1表达对非小细胞肺癌中抗PD-1/PD-L1抗体疗效的预测价值。

Funaishi, Kunihiko; Yamaguchi, Kakuhiro; Tanahashi, Hiroki; Kurose, Koji; Sakamoto, Shinjiro; Horimasu, Yasushi; Masuda, Takeshi; Nakashima, Taku; Iwamoto, Hiroshi; Hamada, Hironobu; Oga, Toru; Oka, Mikio; Hattori, Noboru

Two Cases of Epidermal Growth Factor Receptor L861R Mutation-Positive Lung Adenocarcinoma Treated With Osimertinib and Afatinib

两例表皮生长因子受体L861R突变阳性肺腺癌患者接受奥希替尼和阿法替尼治疗的病例报告

Kagawa, Kei; Masuda, Takeshi; Shimoji, Kiyofumi; Yamaguchi, Kakuhiro; Sakamoto, Shinjiro; Horimasu, Yasushi; Nakashima, Taku; Iwamoto, Hiroshi; Hamada, Hironobu; Hattori, Noboru